The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback